Create a lipid clinic playbook: risk stratification, statin tolerance protocols, add-on…
- User
Create a lipid clinic playbook: risk stratification, statin tolerance protocols, add-on therapy criteria, and monitoring.
- Assistant
Lipid Clinic Playbook
Version 1.0 | Sherlock AI, Trailblazer Labs | Evidence-based on 2018/2019 ACC/AHA, 2019 ESC/EAS, and 2022 updates. Tailor to local guidelines.
This playbook provides actionable algorithms for lipid management in a clinic setting. Prioritize shared decision-making, patient education, and lifestyle optimization (diet, exercise, smoking cessation) as foundation for all patients.
1. Risk Stratification
Classify risk to guide LDL-C goals and intensity of therapy. Use ASCVD Risk Estimator (preferred for US; QRISK3/ESC SCORE for Europe) for primary prevention (ages 40-75, no diabetes/ASCVD).
Primary Prevention Risk Categories & LDL-C Goals
Risk Category 10-Year ASCVD Risk LDL-C Goal Statin Recommendation Low <5% ≥190 mg/dL if untreated High-intensity if LDL-C ≥190 (e.g., FH) Borderline 5-7.5% <100 mg/dL Moderate-intensity; consider if risk enhancers* Intermediate 7.5-<20% <70 mg/dL High-intensity High ≥20% <70 mg/dL High-intensity Very High (DM age ≥50 + risk factors**) N/A <70 mg/dL High-intensity *Risk enhancers: FH, CKD, inflammatory disease, South Asian ancestry, LDL-C ≥160, triglycerides ≥175, ABI <0.9, CAC >0. **DM risk factors: ≥10-year duration, age ≥50, albuminuria, etc.
Secondary Prevention (Established ASCVD)
- LDL-C Goal: <70 mg/dL (ESC: <55 mg/dL).
- Therapy: High-intensity statin + ezetimibe ± PCSK9i if not at goal.
FH Screening
- Dutch Lipid Clinic Network Score or Simon Broome criteria.
- Genetic testing if score ≥6 (probable/definite FH).
Algorithm:
Patient presents → Calculate ASCVD risk → Screen for FH/secondary causes (hypothyroid, nephrotic) → Assign category → Set LDL goal → Start statin.2. Statin Tolerance Protocols
~10-15% report intolerance (mostly myalgias; nocebo effect common). Do not stop without rechallenge.
Stepwise Approach
-
Assess Symptoms: CK if myopathy suspected (pain + weakness). Rule out drug interactions (e.g., fibrates, CYP3A4 inhibitors).
-
Rechallenge Protocol (90% tolerate on retry):
Step Action Examples 1. Reduce Dose 50% dose reduction; continue 4-6 weeks Rosuvastatin 20→10 mg 2. Switch Statin Lower lipophilicity/hydrophilic Atorva → Rosuva/Prava 3. Alternate Day Every other day dosing Rosuva 10 mg M/W/F 4. Low-Potency Pravastatin or fluvastatin Prava 40 mg 5. Non-Statin Bempedoic acid (Nexletol) or ezetimibe first Add to low-dose statin -
Monitoring for Intolerance:
- Baseline: LFTs, CK, lipids.
- Symptoms: Stop if CK >10x ULN + rhabdo.
- Reassess lipids 4-12 weeks post-change.
Red Flags: True myopathy (CK 5-10x ULN), hepatotoxicity (ALT >3x ULN).
3. Add-on Therapy Criteria
If LDL-C not at goal on max tolerated statin (4-12 weeks), escalate per risk.
Escalation Ladder
Step Therapy Criteria/Indications Expected ΔLDL-C 0. Statin Max High-intensity (atorva 40-80 mg, rosuva 20-40 mg) Per risk stratification -50% 1. Ezetimibe 10 mg Add if LDL >goal All; first-line add-on -15-25% 2. PCSK9 Inhibitor (alirocumab 75-150 mg Q2W SC or evolocumab 140 mg Q2W SC) LDL ≥70 mg/dL (primary) or ≥55 (secondary) on statin+ezetimibe ASCVD/FH; prior MI/stroke -50-60% 3. Bempedoic Acid 180 mg QD Statin intolerant; LDL ≥70 Alternative to PCSK9i -18-25% 4. Inclisiran 284 mg SC (0,3,6 then Q6 mo) LDL ≥70 on max therapy Compliance-friendly -40-50% 5. Apheresis/Advanced Homozygous FH; refractory LDL >300 mg/dL N/A Prior Authorization Tips: Document risk, % reduction needed, prior failures.
Triglycerides ≥150 mg/dL:
- Icosapent ethyl (Vascepa 2g BID) if ≥150 + ASCVD/CV risk.
- Avoid niacin/fenofibrate unless TG ≥500.
4. Monitoring Protocol
Goal: Safety, efficacy, adherence.
Schedule
Timepoint Tests/Actions Baseline Lipids (fasting), LFTs, CK, HbA1c, TSH, U/A, BMI. Counsel lifestyle. 4-12 Weeks Lipids (goal check), LFTs/CK if symptoms. Adherence (pill count/MPR). Every 6-12 Mo Lipids, LFTs (annual), adherence/side effects. CAC if intermediate risk. Annually Full panel + ASCVD recalc (if primary). Key Metrics
- LDL-C: Friedewald or direct (if TG >400).
- Non-HDL-C: Alternative goal if needed (<100 high-risk).
- Adherence: >80% MPR → counseling if low.
- Side Effects: Myalgias (SAMS score), new DM (monitor HbA1c).
Flowchart (Text):
Start Therapy → 4-12w Labs → At Goal? → YES: Annual monitor → NO: Escalate → Reassess 4-12w.Clinic Pearls:
- Use apps (e.g., LipidCalc) for calculations.
- Patient handout: "My Lipid Goal Card."
- Multidisciplinary: Refer endo/cardio for FH/PCSK9i.
Update playbook annually or per new guidelines. Sherlock AI: Case solved.